The PURI-HF (Air Purifiers on Heart Failure) Trial
Recruiting · NCT05230784 · Interventional (participants receive a specific treatment) · Lead sponsor: NYU Langone Health
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
Indoor air pollution and fine mode particulate matter with an aerodynamic diameter smaller than 2.5 micrometers (PM2.5) is a major contributor to global morbidity and mortality, particularly due to cardiovascular disease. This project aims to demonstrate the efficacy, feasibility and effectiveness of portable air filters in improving indoor PM2.5 levels and improving functional capacity of heart failure patients with reduced ejection fraction in India. The findings from the project will add to existing knowledge of innovative and scalable strategies to improve environmental and cardiovascular health worldwide. The overall objective of this study is to demonstrate the efficacy, feasibility, and effectiveness of portable air filters in improving indoor PM2.5 levels and improving functional capacity of heart failure patients with reduced ejection fraction in India.
Who can take part
Inclusion criteria
- Adults ≥ 18 years of age diagnosed with HF with a reduced ejection fraction of ≤ 40% within the last six months in NYHA class II-IV.
Exclusion criteria
- listed for a cardiac transplant
- history of CRT device implantation in last 3 months
- on oxygen therapy
- with severe pulmonary disease
- participants unable to ambulate
Where it is running
3 locations listed.
- Centre for Chronic Disease Control (CCDC) - Thiruvananthapuram, Kerala, India
- All India Institute of Medical Sciences (AIIMS) - Delhi, Punjab, India
- Public Health Foundation of India (PHFI) - Ludhiana, Punjab, India